Trinity Biotech
TRIB
81 hedge funds and large institutions have $325M invested in Trinity Biotech in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
8% more funds holding
Funds holding: 75 → 81 (+6)
2% more capital invested
Capital invested by funds: $318M → $325M (+$7.81M)
10% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 29
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
54% less call options, than puts
Call options by funds: $356K | Put options by funds: $781K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$11.3M |
| 2 |
RCMC
RK Capital Management (Colorado)
Denver,
Colorado
|
+$7.5M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$5.89M |
| 4 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$4.42M |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.2M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.5M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.2M |
| 4 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$1.19M |
| 5 |
RA
Royce & Associates
New York
|
-$1.13M |
TRIB Hedge Fund Activity: Q1 2014 in Review
81 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2014, worth a combined $325M — up 2.5% from $318M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TRIB positions and 6 closed out — a net gain of 7 holders — while 26 added to existing stakes and 29 trimmed.
The largest buyer was Cortina Asset Management, opening a new position worth an estimated $11.3M. The largest seller was Fidelity Investments, cutting an estimated $20.2M.
- 81 institutional investors held Trinity Biotech (TRIB) as of Q1 2014, up from 75 in Q4 2013.
- Funds reported $325M of Trinity Biotech stock for Q1 2014, up 2.5% quarter-over-quarter.
- 13 funds opened new Trinity Biotech positions in Q1 2014 and 6 closed out, a net change of +7 holders.
- The largest Trinity Biotech buyer in Q1 2014 was Cortina Asset Management, an estimated $11.3M added.
- The largest Trinity Biotech seller in Q1 2014 was Fidelity Investments, an estimated $20.2M sold.
Based on aggregated 13F filings for Q1 2014.